*you need to join by phone if you want to ask Dr. Sweet your questions.
Immunotherapy continues to be an expanding and evolving area of research for AML, with many drugs in development. One drug currently being studied is IMGN632, an antibody drug conjugate, that targets CD123-positive AML cells. IMGN632 has shown promising results in relapsed/refractory patients in previous AML trials.
Join us live on Thursday, June 9th at 1 PM EST to learn from Dr. Kendra Sweet, an AML expert from Moffitt Cancer Center in Tampa, Florida, about IMGN632, an exciting new immunotherapy investigational agent.
During the show, Dr. Sweet will discuss what IMGN632 is, how it is helping AML patients and the current trial she is participating in that is testing IMGN632 alone, as monotherapy, or when used in combination with other frontline AML drugs. Learn all about immunotherapy and the role it can play when added to existing AML treatment modalities. There will be time at the end of the show to directly ask Dr. Sweet your questions!
Thank you to our episode sponsor, Bristol Myers Squibb.
Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.
Dr. Kendra Sweet is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sweet's clinical interests include myeloid malignancies with a particular focus on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Thank you for your interest in the event. If you have any question, we would love to help! Just fill out the form below and we will get back to you as quickly as possible.